BIOTECH ALLIANCES INCREASE 62% FROM MID 1994-95 COMPARED TO PRIOR YEAR -- ERNST & YOUNG; LATE SUMMER 1995 PUBLIC OFFERING WINDOW HAS RAISED OVER $800 MIL.
Executive Summary
From July 1994 through June 1995, biotech companies looked within the industry for support, forming 62% more alliances compared to the same period the prior year, Ernst & Young's 10th annual industry report "Biotech `96, Pursuing Sustainability" found. The number of alliances between biotech companies grew from 152 during July 1993-June 1994 to 246 in the same 1994-1995 period.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth